Tag Archive for: clinical safety

PTC Therapeutics said on Wednesday its experimental Huntington’s disease drug lowered mutated protein levels that cause the neurological disease, citing interim data from a mid-stage study.

The federal agency granted accelerated approval for Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no other treatment options.